KIT D816 mutated/CBF-negative acute myeloid leukemia

• Verfasst von: Jawhar, Mohamad [VerfasserIn]
• Verfasst von: Kreil, Sebastian [VerfasserIn]
• Verfasst von: Schwaab, Juliana [VerfasserIn]
• Verfasst von: Naumann, Nicole [VerfasserIn]
• Verfasst von: Metzgeroth, Georgia [VerfasserIn]
• Verfasst von: Fabarius, Alice [VerfasserIn]
• Verfasst von: Klein, Stefan [VerfasserIn]
• Verfasst von: Hofmann, Wolf-Karsten [VerfasserIn]
• Verfasst von: Reiter, Andreas [VerfasserIn]
• Titel: KIT D816 mutated/CBF-negative acute myeloid leukemia
• Titelzusatz: a poor-risk subtype associated with systemic mastocytosis
• Verf.angabe: Mohamad Jawhar, Konstanze Döhner, Sebastian Kreil, Juliana Schwaab, Khalid Shoumariyeh, Manja Meggendorfer, Lambert L. F. Span, Stephan Fuhrmann, Nicole Naumann, Hans-Peter Horny, Karl Sotlar, Boris Kubuschok, Nikolas von Bubnoff, Karsten Spiekermann, Michael Heuser, Georgia Metzgeroth, Alice Fabarius, Stefan Klein, Wolf-Karsten Hofmann, Hanneke C. Kluin-Nelemans, Torsten Haferlach, Hartmut Döhner, Nicholas C. P. Cross, Wolfgang R. Sperr, Peter Valent, & Andreas Reiter
• E-Jahr: 2019
• Jahr: 11 January 2019
• Umfang: 11 S.
• Fussnoten: Gesehen am 11.07.2019
• Titel Quelle: Enthalten in: Leukemia
• Ort Quelle: London : Springer Nature, 1997
• Jahr Quelle: 2019
• Band/Heft Quelle: 33(2019), 5, Seite 1124-1134
• ISSN Quelle: 1476-5551
• DOI: doi:10.1038/s41375-018-0346-z
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1669011410

Abstract

KIT D816 mutations (KIT D816mut) are strongly associated with systemic mastocytosis (SM) but are also detectable in acute myeloid leukemia (AML), where they represent an adverse prognostic factor in combination with core binding factor (CBF) fusion genes. Here, we evaluated the clinical and molecular features of KIT D816mut/CBF-negative (CBFneg) AML, a previously uncharacterized combination. All KIT D816mut/CBFneg cases (n = 40) had histologically proven SM with associated AML (SM-AML). Molecular analyses revealed at least one additional somatic mutation (median, n = 3) beside KIT D816 (e.g., SRSF2, 38%; ASXL1, 31%; RUNX1, 34%) in 32/32 (100%) patients. Secondary AML evolved in 29/40 (73%) patients from SM ± associated myeloid neoplasm. Longitudinal molecular and cytogenetic analyses revealed the acquisition of new mutations and/or karyotype evolution in 15/16 (94%) patients at the time of SM-AML. Median overall survival (OS) was 5.4 months. A screen of two independent AML databases (AMLdatabases) revealed remarkable similarities between KIT D816mut/CBFneg SM-AML and KIT D816mut/CBFneg AMLdatabases (n = 69) with regard to KIT D816mut variant allele frequency, mutation profile, aberrant karyotype, and OS suggesting underlying SM in a significant proportion of AMLdatabases patients. Bone marrow histology and reclassification as SM-AML has important clinical implications regarding prognosis and potential inclusion of KIT inhibitors in treatment concepts.